Expect Alembic Pharmaceuticals to touch Rs 280: Bhavin Shah

Bhavin Shah, CEO at Equirus Securities is of the view that Alembic Pharmaceuticals may touch Rs 280. We expect 500 bps margin expansions between FY14-16 and 40 percent earnings compound annual growth rate between FY14-16, he reasoned.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney SME Special
moneycontrol.com

Home » News » Stocks Views

Jan 08, 2014, 10.41 AM | Source: CNBC-TV18

Expect Alembic Pharmaceuticals to touch Rs 280: Bhavin Shah

Bhavin Shah, CEO at Equirus Securities is of the view that Alembic Pharmaceuticals may touch Rs 280. "We expect 500 bps margin expansions between FY14-16 and 40 percent earnings compound annual growth rate between FY14-16," he reasoned.

Like this story, share it with millions of investors on M3

Expect Alembic Pharmaceuticals to touch Rs 280: Bhavin Shah

Bhavin Shah, CEO at Equirus Securities is of the view that Alembic Pharmaceuticals may touch Rs 280. "We expect 500 bps margin expansions between FY14-16 and 40 percent earnings compound annual growth rate between FY14-16," he reasoned.

Post Your Comments

Share Cancel

Bhavin Shah (more)

CEO, Equirus Securities | Capital Expertise: Equity - Fundamental

Bhavin Shah, CEO at Equirus Securities told CNBC-TV18, "We continue to like Sun Pharmaceutical Industries , which was one of our top four picks for 2014, but we initiated coverage of  Alembic Pharmaceuticals couple of days back. We see much bigger upside in Alembic Pharma compared to rest of the pharmaceutical stocks."

He further added, "This is a company that has transformed itself on multiple fronts and we see an upside to Rs 280 on March 2015 basis. That is going to come because we expect 500 bps margin expansions between FY14-16 and 40 percent earnings compound annual growth rate (CAGR) between FY14-16."

"This company is becoming from being purely a domestic to an international generic play and is coming up with a lot of limited competition products and overall becoming a focused company. They have increased their investments in research and development (R&D) and they are beginning to show results. The stock has been a great performer in 2013, but we think there is lot more to come in 2014 as well," Shah said.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Expect Alembic Pharmaceuticals to touch Rs 280: Bhavin Shah

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login